962 related articles for article (PubMed ID: 28267621)
1. Targeting hepatic macrophages to treat liver diseases.
Tacke F
J Hepatol; 2017 Jun; 66(6):1300-1312. PubMed ID: 28267621
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
3. Macrophage heterogeneity in liver injury and fibrosis.
Tacke F; Zimmermann HW
J Hepatol; 2014 May; 60(5):1090-6. PubMed ID: 24412603
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases.
van der Heide D; Weiskirchen R; Bansal R
Front Immunol; 2019; 10():2852. PubMed ID: 31849997
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice.
Baeck C; Wei X; Bartneck M; Fech V; Heymann F; Gassler N; Hittatiya K; Eulberg D; Luedde T; Trautwein C; Tacke F
Hepatology; 2014 Mar; 59(3):1060-72. PubMed ID: 24481979
[TBL] [Abstract][Full Text] [Related]
6. Macrophage Phenotype and Function in Liver Disorder.
Dou L; Shi X; He X; Gao Y
Front Immunol; 2019; 10():3112. PubMed ID: 32047496
[TBL] [Abstract][Full Text] [Related]
7. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2.
Miura K; Yang L; van Rooijen N; Ohnishi H; Seki E
Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(11):G1310-21. PubMed ID: 22442158
[TBL] [Abstract][Full Text] [Related]
8. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.
Tosello-Trampont AC; Landes SG; Nguyen V; Novobrantseva TI; Hahn YS
J Biol Chem; 2012 Nov; 287(48):40161-72. PubMed ID: 23066023
[TBL] [Abstract][Full Text] [Related]
9. Monocytes and macrophages as cellular targets in liver fibrosis.
Heymann F; Trautwein C; Tacke F
Inflamm Allergy Drug Targets; 2009 Sep; 8(4):307-18. PubMed ID: 19534673
[TBL] [Abstract][Full Text] [Related]
10. Dynamic plasticity of macrophage functions in diseased liver.
Ritz T; Krenkel O; Tacke F
Cell Immunol; 2018 Aug; 330():175-182. PubMed ID: 29454647
[TBL] [Abstract][Full Text] [Related]
11. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
12. The innate immune receptor TREM-1 promotes liver injury and fibrosis.
Nguyen-Lefebvre AT; Ajith A; Portik-Dobos V; Horuzsko DD; Arbab AS; Dzutsev A; Sadek R; Trinchieri G; Horuzsko A
J Clin Invest; 2018 Nov; 128(11):4870-4883. PubMed ID: 30137027
[TBL] [Abstract][Full Text] [Related]
13. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis.
Karlmark KR; Weiskirchen R; Zimmermann HW; Gassler N; Ginhoux F; Weber C; Merad M; Luedde T; Trautwein C; Tacke F
Hepatology; 2009 Jul; 50(1):261-74. PubMed ID: 19554540
[TBL] [Abstract][Full Text] [Related]
14. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis.
Zimmermann HW; Tacke F
Inflamm Allergy Drug Targets; 2011 Dec; 10(6):509-36. PubMed ID: 22150762
[TBL] [Abstract][Full Text] [Related]
15. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities.
Wen Y; Lambrecht J; Ju C; Tacke F
Cell Mol Immunol; 2021 Jan; 18(1):45-56. PubMed ID: 33041338
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
Baeck C; Wehr A; Karlmark KR; Heymann F; Vucur M; Gassler N; Huss S; Klussmann S; Eulberg D; Luedde T; Trautwein C; Tacke F
Gut; 2012 Mar; 61(3):416-26. PubMed ID: 21813474
[TBL] [Abstract][Full Text] [Related]
17. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
18. Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo.
Tacke F
Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S27. PubMed ID: 23259611
[TBL] [Abstract][Full Text] [Related]
19. Macrophages in the Aging Liver and Age-Related Liver Disease.
Stahl EC; Haschak MJ; Popovic B; Brown BN
Front Immunol; 2018; 9():2795. PubMed ID: 30555477
[TBL] [Abstract][Full Text] [Related]
20. Liver macrophages in tissue homeostasis and disease.
Krenkel O; Tacke F
Nat Rev Immunol; 2017 May; 17(5):306-321. PubMed ID: 28317925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
